Today's Date: March 29, 2024
Walmart Connect Announced as Presenting Sponsor of the 2024 WIN Summit   •   101 Mobility® Eden Prairie: Leading the Way in Mobility and Accessibility Solutions   •   Naropa University Launches Pioneering Psychedelic Minor     •   Re:wild and Colossal Biosciences team up to leverage revolutionary technology to save critically endangered species on the brink   •   e.l.f. Cosmetics Debuts TikTok Shop Super Brand Day   •   Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment   •   Seniors Helping Seniors® In-Home Care Services Expands to North Houston   •   World Class Dyslexia, Literacy, and Neuroscience Experts Gather with Educators for Two-Day Professional Learning Event   •   AMIGOS FOR KIDS LAUNCHES "THE MISSING REVIEW"   •   Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023   •   Unique online yoga platform offers lifeline for menopausal women   •   Committee for Children Now Offers a PreK-12 Full-Suite Solution with the Highly Anticipated Launch of Second Step® High Scho   •   Navigating Spring Break Sexual Health: Advice from Dr. Deb Laino Sex and Relationship Therapist and Powerful Life Coach   •   Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.   •   Charity Navigator Launches Women's Advocacy List for Women's History Month   •   Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN   •   Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures   •   National University Receives 2024 Military Friendly® Gold Designation   •   Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors   •   Coachella Concerned That People Have Sex, Says AHF
Bookmark and Share

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery pl

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB™ SEAD™, a non-invasive treatment for abnormal uterine bleeding (AUB)

The trial assesses the safety and efficacy of the IUB™ SEAD™, a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy

PR Newswire

MODIIN, Israel, March 4, 2021 /PRNewswire/ -- OCON Healthcare, a women's health company which develops, manufactures and commercializes an innovative 3D intrauterine drug delivery technology based on its patented IUBTM (Intra Uterine Ball) platform, today announced it had completed enrollment of its Phase IIa clinical study evaluating its intrauterine drug delivery platform IUB™ SEAD™,a non-invasive treatment for abnormal uterine bleeding (AUB).

AUB is a medical condition affecting nearly 1 out of 4 women in the reproductive age range (18-50), causing heavy irregular bleeding from the uterus resulting in a significant decrease in their quality of life and even risk of death.

OCON's IUB™ SEAD™ is a disruptive non-invasive treatment for AUB, designed as an alternative to the traditional hormonal medication and/or aggressive and irreversible ablation procedures that are non-reversible and remove the women's chances for later pregnancy, or hysterectomy procedures.

In this clinical study, held in 3 medical centers in Europe, 8 out of the participating 16 patients have reached the End of the Study point, and demonstrated a significant reduction in bleeding. No safety issues were reported to date and all patients were discharged with no complaints. A follow up duration of 12 months is made for each patient post procedure.

"More women and doctors are looking today for innovative and simple solutions to treat AUB," said Prof. Sergio Haimovich, Chief Medical Officer at OCON Healthcare. "The IUB™ SEAD™ solves this medical condition, which negatively impacts the health and the quality of life of 25% of all women in their reproductive years,  with no need for irreversible ablation techniques or hysteractomies. This ground breaking technology already made a positive impact on womens lives and we are certain we will see more of it during our clinical studies in the near future."

As far as the OCON is aware, the global AUB surgery market is expected to reach $1.3 billion by 2024, with 1.4 million women per year who report AUB.

CONTACT

Ravit Levrann

ravit@theinvestor.co.il

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/femtech-startup-ocon-healthcare-announces-last-patient-in-phase-iia-clinical-study-evaluating-its-intrauterine-drug-delivery-platform-iub-sead-a-non-invasive-treatment-for-abnormal-uterine-bleeding-aub-301240430.html

SOURCE OCON Healthcare



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News